Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the global first quarter net sales of OLYSIO® (simeprevir) amounted to 32 MUSD.
The royalty for the first quarter amounted to 18 MSEK (2.0 MEUR). Medivir’s royalties based on sales for the first quarter are calculated from the first royalty tier.
| OLYSIO® global net sales | Sales in MUSD | ||
| Market | Q1 -2016 | Q1-2015 | Change |
| US | 16 | 98 | -84% |
| RoW | 16 | 136 | -88% |
| Total global net sales MUSD | 32 | 234 | -86% |
Going forward royalty for OLYSIO® will be disclosed only in the interim reports and not announced separately, unless world-wide sales materially increase.
The Interim Report for January – March 2016 will be published on 28 April 2016, at 8.30 CET, followed by a conference call for investors, analysts and the media at 14.00 CET. More information about the conference call/webcast will be posted at www.medivir.com.
For further information, please contact:
Ola Burmark, CFO Medivir AB, mobile: +46 (0) 725 480 580
Medivir is required under the Securities Markets Act to make the information in this press release public.
The information was submitted for publication at 14:30 CET on 19thof April 2016.
About Medivir
Medivir is a research based pharmaceutical company with a research focus on oncology and infectious diseases. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Our commercial organization provides a portfolio of specialty care pharmaceuticals on the Nordic market.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.